# Azienda Ospedaliera S.Maria

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/azienda-ospedaliera-s-maria/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 90 |
| Citations | 185,709 |
| City | Terni |
| Country | IT |
| Description | Azienda Ospedaliera S.Maria is a research organisation in Terni, IT. OpenAlex records 3,114 works and 185,709 citations for it. 794 researchers list it as their most recent affiliation. |
| Homepage | http://www.aospterni.it/ |
| OpenAlex ID | https://openalex.org/I4210123105 |
| Researchers | 794 |
| ROR ID | https://ror.org/02t96cy48 |
| Type | healthcare |
| Works | 3,114 |

## University papers

Showing 12 of 15.

- [Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#](https://scholariq.org/papers/antimicrobial-therapeutic-drug-monitoring-in-critically-ill-adult-patients-a/)
- [European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)](https://scholariq.org/papers/european-society-of-clinical-microbiology-and-infectious-diseases-escmid/)
- [Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy](https://scholariq.org/papers/predictors-of-mortality-in-bloodstream-infections-caused-by-klebsiella/)
- [Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-cefiderocol-or-best-available-therapy-for-the-treatment/)
- [Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data](https://scholariq.org/papers/effectiveness-of-neuraminidase-inhibitors-in-reducing-mortality-in-patients/)
- [Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study](https://scholariq.org/papers/infections-caused-by-kpc-producing-i-klebsiella-pneumoniae-i-differences-in/)
- [ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms](https://scholariq.org/papers/enets-consensus-guidelines-update-for-gastroduodenal-neuroendocrine-neoplasms/)
- [Bloodstream infections in critically ill patients: an expert statement](https://scholariq.org/papers/bloodstream-infections-in-critically-ill-patients-an-expert-statement/)
- [Persistence of Increased Cardiovascular Risk in Patients with Cushing’s Disease after Five Years of Successful Cure](https://scholariq.org/papers/persistence-of-increased-cardiovascular-risk-in-patients-with-cushing-s-disease/)
- [Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial](https://scholariq.org/papers/colistin-and-rifampicin-compared-with-colistin-alone-for-the-treatment-of/)
- [ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms](https://scholariq.org/papers/enets-consensus-guidelines-update-for-colorectal-neuroendocrine-neoplasms/)
- [Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology](https://scholariq.org/papers/risk-factors-and-outcome-of-pulmonary-aspergillosis-in-critically-ill/)

## University top topics

Showing 8 of 25.

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.